Lilly and Princeton File Third IP-Infringement Suit Against Generic Makers for Alimta Patent | GenomeWeb

Eli Lilly and Princeton University are suing generic drugmaker Barr Laboratories in a federal court for allegedly infringing a US patent owned by Princeton and exclusively licensed to Lilly as the basis for its blockbuster lung cancer chemotherapeutic Alimta.

The suit is the third filed by co-plaintiffs Lilly and Princeton against generic drug makers looking to manufacture a knock-off of the drug prior to the patent's expiration in an effort to protect their interest in a compound that generated more than $1 billion in revenues last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.